Lianglong Chen MD PhD FACC

Slides:



Advertisements
Similar presentations
IVUS Use during Left Main PCI improve Immediate and Long Term Outcome Where is the Evidence? E Murat Tuzcu, MD, FACC Professor of Medicine Vice Chairman.
Advertisements

Lésion du tronc commun : reste-t-il une place pour la chirurgie ? La vision de l’angioplasticien Y. Louvard, ICPS, Massy.
Is this the “spioenkop” for CABG?
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
A multicenter, randomized, prospective DKCRUSH-III study
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.
BIFURCATION LESIONS Dr. Tahsin.N
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
PCI VS CABG JOURNAL REVIEW
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Left Main Stem Intervention Trials & Registries Keith D. Dawkins MD FRCP FACC Southampton University Hospital UK.
LM strategy Interventional cardiology dpt Cardiovascular Hospital - Lyon - France Gilles Rioufol MD PhD INSERM U1060 High Tech Marseille, 26 Janvier 2012.
TCT 2012 Revascularization Strategies for Complex Left Main Disease and Left Coronary Ostial Disease Alfredo E. Rodriguez, MD, PhD, FACC, FSCAI Centro.
左主干分叉病变治疗策略的选择 Left main bifurcation: what is the best choice? Lei Ge, MD Department of Cardiology, Zhongshan Hospital, Fudan University.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
USCV September of 25 The safety and effectiveness of the TAXUS Express2 Stent System have not been established in the following patient.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.
Dedicated Bifurcation Stent Technology: Implications for Everyday Practice Jens Flensted Lassen MD, PH.D., FESC The Heart Centre, Rigshospitalet University.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prospective Application of Pre-Defined Intravascular.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Multivessel PCI in an Era of Freedom and FAME Michael J. Cowley, MD, FSCAI Nothing to Disclose.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.
J Am Coll Cardiol 2008;51:538–45 Acute and Late Outcomes of Unprotected Left Main Stenting in Comparison With Surgical Revascularization Pawel E. Buszman,
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different.
Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Prof. Dr. med. Sigmund Silber Cardiology Practice and Hospital
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
(DES)+BVS +DCB for long diffuse LAD disease
Strategy planning in coronary bifurcation stenting
BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.
Giuseppe Biondi Zoccai, MD
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
FOR DISTRIBUTION BY MEDTRONIC OFFICE OF MEDICAL AFFAIRS ONLY.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Presented at TCT 2006.
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

无保护左主干分叉病变介入治疗策略 The Principles & Strategies for Treatment of Unprotected LM Bifurcation Lesions Lianglong Chen MD PhD FACC Dept. of Cardiology, Union Hospital, Fujian Medical University

CONTENTS & FOCI Special issues associated with LMD & special considerations Different strategies and techniques for the Intervention of UPLMD Comparison of PCI versus CABG for the treatment of UPLMD Current guidelines and recommendations for the treatment of UPLMD

Why left main lesion is particular? LM is responsible for 75% myocardial blood supplying LM is anatomically big with 2 bifurcation & larger angulations LM is rich in elastic tissue Plaque is usually located in the lateral wall close to the LAD and LCx bifurcation, the carina is frequently free of disease. Plaque of LMD is more diffuse Low shear- stress zone High shear- stress zone carina

Why left main lesion is particular? Plaque of LMD is more diffuse, 90% LM plaque extended to LAD

Special considerations for UPLMD Intervention Reliable branch protection Protecting wire Protecting balloon Effective lesion preparation Pre-dilation Pre-cutting balloon Pre-rotablation First & final balloon kissing DK-crush DK-culotte Special imaging IVUS guiding procedure FFR guiding procedure

Culottes: DK-Mini-Culottes

FBKI: key determinants of restnosis, thrombusis, MI

CONTENTS & FOCI Special issues associated with LMD & special considerations Different strategies and techniques for the Intervention of UPLMD Comparison of PCI versus CABG for the treatment of UPLMD Current guidelines and recommendations for the treatment of UPLMD

Different strategies for the Intervention of UPLMD Simple vs complex Mono-stent vs dual-stents

MACE and TLR in Bifurcation Studies CACTUS BBC ONE BBK Nordic P=0.009

Double vs. Single Stenting Meta-Analysis N=1642 pts 2 stents 1 stent 2 stents 1 stent Katritsis DG et al. Circ Cardiovasc Intervent. 2009;2:409-415

Double vs. Single Stenting Meta-Analysis N=1642 pts 2 stents 1 stent 2 stents 1 stent Katritsis DG et al. Circ Cardiovasc Intervent. 2009;2:409-415

Shao-Liang Chen EuroIntervention 2012;8:803-814 Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent versus two-stent techniques versus double-kissing crush technique To compare the long-term (five-year) safety and efficacy between the one-stent, two-stent and double-kissing (DK) crush strategies, utilising drug-eluting stents, for unprotected left main coronary artery (ULMCA) bifurcation lesions Shao-Liang Chen EuroIntervention 2012;8:803-814

MACE-free survival rates at 5-year follow-up

Survival rates free from cardiac death, MI, and TVR at 5-year follow-up

Current consensus or guideline recommendation Simple strategies!

UPLMD: Cases

The optimal Path for BL Treatment 

Different techniques for the Intervention of UPLMD Superiority of one dual-stenting technique over the others ?

Nordic II: Rate of Restenosis (≥50% diameter stenosis by QCA) at 8M In-segment In-stent

Nordic II: Major Adverse Cardiac Events at 6 Months Follow-up Cumulated MACE rate (cardiac death, MI, TVR, stent thrombosis) Crush 4.3%, Culotte 3.7% (plog-rank=0.87). Erglis A et al. Circ Cardiovasc Intervent, 2009; 2:27-34

Shao-Liang Chen, et al. J Am Coll Cardiol 2013;61:1482–8 Comparison of Double Kissing Crush Versus Culotte Stenting for Unprotected Distal Left Main Bifurcation Lesions Results From a Multicenter, Randomized, Prospective DKCRUSH-III Study Shao-Liang Chen, et al. J Am Coll Cardiol 2013;61:1482–8

DK-crush vs classic culotte TLR TVR MACE

Conclusions Classic culotte stenting for UPLMCA bifurcation lesions was associated with significantly increased MACEs, mainly due to the increased TVR.

Shao-Liang Chen EuroIntervention 2012;8:803-814 Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent versus two-stent techniques versus double-kissing crush technique To compare the long-term (five-year) safety and efficacy between the one-stent, two-stent and double-kissing (DK) crush strategies, utilising drug-eluting stents, for unprotected left main coronary artery (ULMCA) bifurcation lesions Shao-Liang Chen EuroIntervention 2012;8:803-814

Survival rates free from MACE, TLR, and TVR at 5 years between DK crush and other two-stent techniques MACE TLR TVR

Major limitation of classic culotte:CUEB D4.0 D2.5

Culottes: DK-Mini-Culottes

DK-Mini-Culottes: no CUEB

Long-term results at F/U 61 pts Lesion characteristics with 85%TBL, 25% UPLM. Branch diameter difference 0.450.24. DK-Mini-Culottes Immediate technical success 100% FKBI 100% Acute IST 0.0% F/U 11.31.5 M Binary re-stenosis Main branch 6.6% Side branch 16.4% MACE Death 0.0% MI 0.0% TLR 3.2% Late IST 0.0%

Different techniques for the Intervention of UPLMD Superiority of one dual-stenting technique over the others ???

CONTENTS & FOCI Special issues associated with LMD & special considerations Different strategies and techniques for the Intervention of UPLMD Comparison of PCI versus CABG for the treatment of UPLMD Current guidelines and recommendations for the treatment of UPLMD

MACCE to 5 Years by SYNTAX Score Tercile Low Scores (0-22)

MACCE to 5 Years by SYNTAX Score Tercile Intermediate Scores (33)

Patient Characteristics CABG N=897 PCI N=903 CABG Registry N=644 PCI Registry N=192 P value Age* (y) Male, % Diabetes*†, % Additive euroSCORE* Total Parsonnet score* 65.0±9.8 78.9 24.6 3.8±2.7 8.4±6.8 65.2±9.7 76.4 25.6 3.8±2.6 8.5±7.0 0.55 0.20 0.64 0.78 0.76 65.7±9.4 80.7 26.4 3.9±2.7 9.0±7.1 71.2±10.4 70.3 30.2 5.8±3.1 14.4±9.5 Total SYNTAX Score 29.1±11.4 28.4±11.5 0.19 37.8±13.3 31.6±12.3 Mean # of lesions 3VD only, % Left main, any, % Total occlusion, % Complete revasc, % 4.4±1.8 66.3 33.7 22.2 63.2 4.3±1.8 65.4 34.6 24.2 56.7 0.44 0.70 0.33 0.005 4.6±1.7 59.7 40.3 56.4 74.7 4.5±1.8 66.7 33.3 36.5

MACCE to 5 Years by SYNTAX Score Tercile Low Scores (0-22) CABG (N=275) TAXUS (N=299) CABG 10.1% PCI 8.9% P value 0.64 Overall Death 50 Cumulative Even Rate(%) CVA MI Death, CVA or 4.0% 4.2% 14.9% 1.8% 7.8% 16.1% 0.11 0.81 32.1% 28.6% P=0.43 25 12 24 36 48 60 Months Since Allocation Revasc. 16.9% 23.0% 0.06 Cumulative KM Event Rate ± 1.5 SE; log-rank P value Core lab-reported Data; ITT population

MACCE to 5 Years by SYNTAX Score Tercile Intermediate Scores (23-32) CABG (N=300) TAXUS (N=310) P=0.008 CABG 12.7% 3.6% PCI 13.8% 2.0% P value 0.68 0.25 Overall 36.0% Death CVA 50 Cumulative Even Rate(%) MI Death, CVA or 3.6% 18.0% 11.2% 20.7% <0.001 0.42 25 25.8% 12 24 36 48 60 Months Since Allocation Revasc. 12.7% 24.1% <0.001 Cumulative KM Event Rate ± 1.5 SE; log-rank P value Core lab-reported Data; ITT population

MACCE to 5 Years by SYNTAX Score Tercile Intermediate Scores (33) CABG (N=315) TAXUS (N=290) P<0.001 CABG 11.4% PCI 19.2% P value 0.005 Overall Death 50 Cumulative Even Rate(%) CVA MI 3.7% 3.9% 3.5% 10.1% 0.80 0.004 44.0% 25 26.8% Death, CVA or MI 17.1% 26.1% 0.007 12 24 36 48 60 Months Since Allocation Revasc. 12.1% 30.9% <0.001 Cumulative KM Event Rate ± 1.5 SE; log-rank P value Core lab-reported Data; ITT population

SYNTAX UPLMD subgroup analysis at 3 years The UPLMD subgroup (N=705); despite higher TVR for the PCI group at 3 yrs (20.0% PCI vs 11.7% CABG; P=0.004) and lower stroke in the PCI group (1.2% PCI vs 4.0% CABG; P=0.02); Death (7.3% PCI vs 8.4% CABG; P=0.64), MI (6.9% PCI vs 4.1% CABG; P=0.14), and the composite end point of death/MI/stroke (13.0% PCI vs 14.3% CABG; P=0.60) remained similar between groups. These results are consistent reporting similar safety outcomes between PCI and CABG but a higher rate of TVR with PCI.

Rev Bras Cir Cardiovasc 2013;28(1):83-92 Five-year outcomes following PCI with DES versus CABG for unprotected LM coronary lesions: meta-analysis and meta-regression of 2914 patients To compare the safety and efficacy at long-term follow-up of coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) using drug-eluting stents (DES) in patients with unprotected left main coronary artery (ULMCA) disease Rev Bras Cir Cardiovasc 2013;28(1):83-92

Odds ratio and conclusions plot of endpoints associated with CABG versus DES 死亡、MI、中风 死亡 MACE TVR

Conclusion CABG surgery remains the best option of treatment for patients with ULMCA disease, with less need of TVR and MACCE rates at long-term follow-up

FREEDOM Design

Primary Outcome-Death/Stroke/MI

Outcomes 全因死亡 MI 中风 TVR

Primary Outcome-Death/Stroke/MI

Conclusion For patients with UPLMD complicating DM, CABG surgery is the only best option of treatment with no more requirement of Syntax score

CONTENTS & FOCI Special issues associated with LMD & special considerations Different strategies and techniques for the Intervention of UPLMD Comparison of PCI versus CABG for the treatment of UPLMD Current guidelines and recommendations for the treatment of UPLMD

2011 ACCF/AHA/SCAI Guideline for PCI: recommendations

Thanks!